Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A F Kurz

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
International Journal of Clinical Practice. Supplement|June 16, 2001
What is vascular dementia?A F Kurz
Dementia and Geriatric Cognitive Disorders|October 13, 2001
Primary degenerative mild cognitive impairment: study population, clinical, brain imaging and biochemical findingsN T Lautenschlager, M Riemenschneider, A Drzezga, et al.
European Journal of Neurology|December 3, 2003
Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular diseaseA F Kurz, T Erkinjuntti, G W Small, et al.
Clinical Therapeutics|June 9, 2001
Therapeutic continuity in Alzheimer's disease: switching patients to galantamine. Panel discussion: recommendations for prescribersJ C Morris, M R Farlow, S H Ferris, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
International Journal of Clinical Practice. Supplement|June 16, 2001
What is vascular dementia?A F Kurz
Dementia and Geriatric Cognitive Disorders|October 13, 2001
Primary degenerative mild cognitive impairment: study population, clinical, brain imaging and biochemical findingsN T Lautenschlager, M Riemenschneider, A Drzezga, et al.
European Journal of Neurology|December 3, 2003
Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular diseaseA F Kurz, T Erkinjuntti, G W Small, et al.
Clinical Therapeutics|June 9, 2001
Therapeutic continuity in Alzheimer's disease: switching patients to galantamine. Panel discussion: recommendations for prescribersJ C Morris, M R Farlow, S H Ferris, et al.
Pageof 1